Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ⌧ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the year ended December 31, 2020 or ◻ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number 001-38410 BioXcel Therapeutics, Inc. (Exact name of Registrant as specified in its charter) | --- | --- | --- | --- | --- | ...

NASDAQ: BTAI | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | Developing and Commercializing Innovative Medicines Discovered using AI November 2020 | | | | | | | | | | | | | | | | | | | | Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking ...

Call Start: 08:30 January 1, 0000 9:10 AM ET BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2020 Earnings Conference Call November 12, 2020 08:30 ET Company Participants Vimal Mehta - Chief Executive Officer Richard Steinhart - Chief Financial Officer Will Kane - Chief Commercial Officer Reina Benabou - Chief Development Officer Vince O'Neill - Chief Medical Officer Robert Risinger - Senior Vice President of Clinical Development Frank Yocca - Chief Scientific Officer Conference Call Participants Geoff Meacham ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38410 BioXcel Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-13867 ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q2 2020 Earnings Conference Call August 14, 2020 8:30 AM ET Company Participants Vimal Mehta – Chief Executive Officer Michael Stanton – Controller Rob Risinger – Senior Vice President-Clinical Development Will Kane – Chief Commercial Officer Reina Benabou – Chief Development Officer Conference Call Participants Geoff Meacham – Bank of America Robyn Karnauskas – Truist Securities Yatin Suneja – Guggenheim Partners Sumant Kulkarni – Canaccord Ram Selvaraju – H.C. Wain ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38410 BioXcel Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1386754 (S ...

NASDAQ: BTAI | --- | --- | --- | --- | |-----------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Next Wave of Medicines Utilizing AI June 2020 | | | | | | | | | | | | | | Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, but are not limited to, statements that relate to the advancement a ...

NASDAQ: BTAI | --- | --- | --- | --- | --- | |----------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Next Wave of Medicines Utilizing AI May 2020 | | | | | | | | | | | | | | | | | | | | | | | Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, but are not limit ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38410 BioXcel Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82‑1386754 ( ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2020 Results Conference Call May 12, 2020 8:30 AM ET Company Participants Vimal Mehta - Founder and CEO Richard Steinhart - VP and CFO Frank Yocca - SVP and Chief Scientific Officer Vincent O'Neill - SVP and Chief Medical Officer Rob Risinger - VP, Clinical Development Conference Call Participants Scott Puckhaber - Bank of America Robyn Karnauskas - SunTrust Robinson Humphrey Guyn Kim - BMO Capital Markets Sumant Kulkarni - Canaccord Samir Devani - RX Securities O ...